RecruitingNot ApplicableNCT06639425

Efficacy of Lactobacillus Paracasei LC19 on Type 2 Diabetes

Efficacy of Lactobacillus Paracasei LC19 on Newly Diagnosed Type 2 Diabetes


Sponsor

Beijing Chao Yang Hospital

Enrollment

60 participants

Start Date

Oct 12, 2024

Study Type

INTERVENTIONAL

Conditions

Summary

This is a randomized, double-blind, placebo-controlled clinical trial. The objective of this trial is to determine whether Lactobacillus paracasei LC19 supplementation has a positive effect on glucose lowering in patients with type 2 diabetes (T2D).


Eligibility

Min Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This study tests whether Lactobacillus paracasei LC19, a specific probiotic strain, can help improve blood sugar control in people who have just been diagnosed with Type 2 diabetes and have not yet started any diabetes medications. **You may be eligible if...** - You are 18–65 years old (any gender) with a newly diagnosed Type 2 diabetes - You have not yet started any diabetes medication - Your HbA1c (a 3-month blood sugar average) is between 7.0% and 9.0% - You have no other types of diabetes and no serious heart, liver, kidney, or thyroid conditions **You may NOT be eligible if...** - You have Type 1 diabetes, gestational diabetes, or secondary diabetes - You have had a heart attack, stroke, or serious heart condition in the past 6 months - You have active liver disease, kidney disease, or thyroid problems - You have had hypoglycemia (dangerously low blood sugar) in the past 6 months - You are pregnant, breastfeeding, or planning to become pregnant - You have significant digestive disorders or recent bowel surgery Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTLactobacillus paracasei LC19 supplementation

Orally administered Lactobacillus paracasei LC19 strain product, in addition to lifestyle intervention. This product is a probiotic milk powder, and the Lactobacillus paracasei LC19 strain is capable of producing high levels of tryptophan-conjugated cholic acid (Trp-CA)( 25g/packet, 2 packets/day).

DIETARY_SUPPLEMENTPlacebo probiotic milk powder

Orally administered placebo probiotic milk powder, in addition to lifestyle intervention. The placebo probiotic strain also belongs to Lactobacillus paracasei species, but does not produce Trp-CA. These products have the same color, odor, appearance, and packaging (25g/packet, 2 packets/day).


Locations(1)

Beijing Chao-yang Hospital, Capital Medical University

Beijing, Beijing Municipality, China

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06639425


Related Trials